DC-PGKI
DC-PGKI is an orally active ATP-competitive PGK1 inhibitor(IC50 = 0.16 Μm, Kd = 99.08 nM). DC-PGKI stabilizes PGK1 in vitro and in vivo, and suppresses both glycolytic activity and the kinase function of PGK1. DC-PGKI-mediated inhibition of PGK1 leads to the accumulation of NRF2 (nuclear factor-erythroid factor 2-related factor 2, NFE2L2), which then translocates to the nucleus, binds to the proximal regions of IL-1β and IL-6 genes, and suppresses the LPS-induced expression of these genes. DC-PGKI can be used for the study of colitis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2829198-49-2
- 화학식: C26H29Cl2N7O3
- 분자량:558.46
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
PGK1 0.16 μM (IC50) |
PGK1 99.08 nM (Kd) |
IL-6 |
IL-1β |
In Vitro
DC-PGKI (0.1-30 μM, 3 h) can increase RAW264.7 cells' PGK1 thermal stability in a concentration-dependent manner[1].
DC-PGKI (5-10 μM, 10 h) inhibits PGK1 glycolytic metabolic activity in the resting and activated in RAW264.7 cells[1].
DC-PGKI (10-20 μM) notably decreases the Ser30 phosphorylation level of Beclin1 in RAW246.7 cells, indicating that DC-PGKI also impairs PGK1’s kinase function[1].
DC-PGKI (5-20 μM) inhibits LPS-induced IL-1β and IL-6 mRNA in a concentration-dependent manner in RAW246.7 cells[1].
DC-PGKI (0-20 μM) significantly inhibits Lipopolysaccharides (HY-D1056) (LPS)-induced precursor of IL-1β and IL-6 in RAW264.7 cells[1].
DC-PGKI (5-20 μM, 7 h) results in a significant reduction in KEAP1 protein level, accumulation of NRF2, as well as upregulation of both the mRNA and protein levels of HMOX1 in LPS-induced RAW264.7 cells[1].
DC-PGKI (5-20 μM, 7 h) upregulates other downstream target genes of NRF2, including Txnrd1, Prdx1, Gclc, Sod1, Fth1, and Ephx1, in both LPS-treated and untreated conditions in RAW264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 cells
-
Concentration:0 μM, 0.1 μM, 0.5 μM, 1 μM, 5 μM, 10 μM, 20 μM, 30 μM
-
Incubation Time:3 h
-
Result:Increased RAW264.7 cells' PGK1 thermal stability in a concentration-dependent manner.
-
Cell Line:RAW264.7 cells were stimulated with LPS (1 μg/mL) for 4 hours.
-
Concentration:5 μM, 10 μM, 20 μM
-
Incubation Time:7 h
-
Result:Inhibited the mRNA expression of IL-1β and IL-6.
Resulted in a significant reduction in KEAP1 protein level, accumulation of NRF2, as well as upregulation of both the mRNA and protein levels of HMOX1.
Upregulated other downstream target genes of NRF2, including Txnrd1, Prdx1, Gclc, Sod1, Fth1, and Ephx1.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUClast | MRTINF_obs | F | AUCINF_obs | Vss_obs |
|---|---|---|---|---|---|---|---|---|---|---|
| Mice | 10 mg/kg | p.o. | 5.29 h | 4 h | 38 ng/mL | 253 ng·h/mL | 8.1 h | 11.2 % | / | / |
| Mice | 3 mg/kg | i.v. | 4.35 h | / | / | 676 ng·h/mL | 5.36 h | / | 755 ng·h/mL | 22362 mL/kg |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-week-old C57BL/6 male mice were given 5%(w/v) DSS for 7 days to induce acute colitis, followed by drinking water for one day[1].
-
Dosage:5 mg/kg, 10 mg/kg
-
Administration:P.o., once daily for 8 days
-
Result:Significantly reduced weight loss induced by DSS.
The disease activity index (DAI) decreased compared to the DSS group.
Reduced colonic tissue damage, lymphocyte infiltration, and crypt destruction.
Lowered serum and tissue protein and mRNA levels of IL-1β and IL-6.
Increased NRF2 protein accumulation in colonic tissue.
Chemical Information
-
CAS No. 2829198-49-2
-
분자량 558.46
-
화학식 C26H29Cl2N7O3
-
SMILES
O=C(N1CCN(C2=NC3=C(N=C2C(OCC)=O)C=C(Cl)C(Cl)=C3)CC1)NC(C=C4)=CC=C4N5CCNCC5
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)